

Highlights of This Issue 1

SMALL MOLECULE THERAPEUTICS

- 3** **Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors**
Anthony W. Tolcher, Wei Peng, and Emiliano Calvo
- 17** **Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations**
Tadaaki Yamada, Joseph M. Amann, Azusa Tanimoto, Hirokazu Taniguchi, Takehito Shukuya, Cynthia Timmers, Seiji Yano, Konstantin Shilo, and David P. Carbone
- 26** **Pharmacologic Inhibition of the Menin–MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma**
Katarzyna Kempinska, Bhavna Malik, Dmitry Borin, Szymon Klossowski, Shirish Shukla, Hongzhi Miao, Jingya Wang, Tomasz Cierpicki, and Jolanta Grembecka
- 39** **Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer**
Anindya Dey, Xunhao Xiong, Aleia Crim, Shailendra Kumar Dhar Dwivedi, Soumyajit Banerjee Mustafi, Priyabrata Mukherjee, Liangxian Cao, Nadiya Sydorenko, Ramil Baiazitov, Young-Choon Moon, Melissa Dumble, Thomas Davis, and Resham Bhattacharya
- 50** **Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer**
Xuewei Zhang, Kazuyuki Kitatani, Masafumi Toyoshima, Masumi Ishibashi, Toshinori Usui, Junko Minato, Mahy Egiz, Shogo Shigeta, Todd Fox, Tye Deering, Mark Kester, and Nobuo Yaegashi
- 60** **Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic *In Vitro* and *In Vivo* Antitumor Effects in Insulinoma Cells**
Julien Bollard, Céline Patte, Patrick Massoma, Isabelle Goddard, Nicolas Gadot, Noura Benslama, Valérie Hervieu, Carole Ferraro-Peyret, Martine Cordier-Bussat, Jean-Yves Scoazec, Colette Roche, Thomas Walter, and Cécile Vercherat

- 73** **Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines**
Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, and Keiran S.M. Smalley
- 84** **Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas *In Vivo* and *Ex Vivo***
Edward J. Hartsough, Curtis H. Kugel, III, Michael J. Vido, Adam C. Berger, Timothy J. Purwin, Allison Goldberg, Michael A. Davies, Matthew J. Schiewer, Karen E. Knudsen, Gideon Bollag, and Andrew E. Aplin
- 96** **Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages**
Courtney A. Penn, Kun Yang, Hong Zong, Jae-Young Lim, Alex Cole, Dongli Yang, James Baker, Sascha N. Goonewardena, and Ronald J. Buckanovich
- 107** **JQ1 Induces DNA Damage and Apoptosis and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma**
Patrick L. Garcia, Aubrey L. Miller, Tracy L. Gamblin, Leona N. Council, John D. Christein, J. Pablo Arnoletti, Marty J. Heslin, Sushanth Reddy, Joseph H. Richardson, Xiangqin Cui, Robert C.A.M. van Waardenburg, James E. Bradner, Eddy S. Yang, and Karina J. Yoon
- 119** **Targeted Delivery of STAT-3 Modulator to Breast Cancer Stem-Like Cells Downregulates a Series of Stemness Genes**
Santosh K. Misra, Arun De, and Dipanjan Pan
- 130** **miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases**
Yuanzheng Yang, Gangxiong Huang, Zhichao Zhou, Jason G. Fewell, and Eugenie S. Kleinerman

LARGE MOLECULE THERAPEUTICS

- 140** **HIF2 α -Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma**
So C. Wong, Weijun Cheng, Holly Hamilton, Anthony L. Nicholas, Darren H. Wakefield, Aaron Almeida, Andrei V. Blokhin, Jeffrey Carlson, Zane C. Neal, Vladimir Subbotin, Guofeng Zhang, Julia Hegge, Stephanie Bertin, Vladimir S. Trubetskoy, David B. Rozema, David L. Lewis, and Steven B. Kanner

Table of Contents








- 150** **IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma**
 Thomas M. Cardillo, Serengulam V. Govindan, Maria B. Zalath, Diane L. Rossi, Yang Wang, Chien-Hsing Chang, and David M. Goldenberg
- 161** **CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models**
Penelope M. Drake, Adam Carlson, Jesse M. McFarland, Stefanie Bañas, Robyn M. Barfield, Wesley Zmolek, Yun Cheol Kim, Betty C.B. Huang, Romas Kudirka, and David Rabuka
- 169** **Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer**
Ran Li, Srinivas Chiguru, Li Li, Dongyoung Kim, Ramraj Velmurugan, David Kim, Siva Charan Devanaboyina, Hong Tian, Alan Schroit, Ralph P. Mason, Raimund J. Ober, and E. Sally Ward
- 183** **A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin–Drug Conjugate (LDC)**
 Osamu Shimomura, Tatsuya Oda, Hiroaki Tateno, Yusuke Ozawa, Sota Kimura, Shingo Sakashita, Masayuki Noguchi, Jun Hirabayashi, Makoto Asashima, and Nobuhiro Ohkohchi
- 196** **Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)**
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Jennifer Donnell, Jing Xia, Edmund A. Rossi, Chien-Hsing Chang, and David M. Goldenberg
- 204** **Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol**
Hannah E. Pearson, Mari Iida, Rachel A. Orbuch, Nellie K. McDaniel, Kwangok P. Nickel, Randall J. Kimple, Jack L. Arbiser, and Deric L. Wheeler
- 215** **Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors**
Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, Antonio Jimeno, Cindy L. O'Bryant, Ramesh K. Ramanathan, Glen J. Weiss, Manpreet Chadha, Abbie Oey, Han Ting Ding, Patricia A. Culp, Stephan F. Keller, Vivian Y. Zhao, L. Claire Tsao, Anil Singhal, Kyle D. Holen, and Daniel Von Hoff
- CANCER BIOLOGY AND TRANSLATIONAL STUDIES**
- 222** **ALK Inhibitor Response in Melanomas Expressing *EML4-ALK* Fusions and Alternate *ALK* Isoforms**
Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, Stacey M. Bagby, Danielle Murphy, Jason Christiansen, Jennifer D. Hintzsche, Anh Le, Todd M. Pitts, Keith Wells, Allison Applegate, Carol Amato, Pratik Multani, Edna Chow-Maneval, John J. Tentler, Yiqun G. Shellman, Matthew J. Rieth, Aik-Choon Tan, Rene Gonzalez, Theresa Medina, Robert C. Doebele, and William A. Robinson
- 232** **Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3 β**
 Wen Min Lau, Eileen Teng, Kie Kyon Huang, Jin Wei Tan, Kakoli Das, Zhijiang Zang, Tania Chia, Ming Teh, Koji Kono, Wei Peng Yong, Asim Shabbir, Amy Tay, Niam Sin Phua, Patrick Tan, Shing Leng Chan, and Jimmy Bok Yan So
- 243** **Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)**
 Matthew Sung, Xingzhi Tan, Bingwen Lu, Jonathan Golas, Christine Hosselet, Fang Wang, Laurie Tylaska, Lindsay King, Dahui Zhou, Russell Dushin, Jeremy S. Myers, Edward Rosfjord, Judy Lucas, Hans-Peter Gerber, and Frank Loganzo
- 254** **AKT1^{low} Quiescent Cancer Cells Promote Solid Tumor Growth**
 Cleidson P. Alves, Ipsita Dey-Guha, Sheheryar Kabraji, Albert C. Yeh, Nilesh P. Talele, Xavier Solé, Joeeta Chowdhury, Mari Mino-Kenudson, Massimo Loda, Dennis Sgroi, Anne-Lise Borresen-Dale, Hege G. Russnes, Kenneth N. Ross, and Sridhar Ramaswamy
- 264** **Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer**
Alexander Beatty, Lauren S. Fink, Tanu Singh, Alexander Strigun, Erik Peter, Christina M. Ferrer, Emmanuelle Nicolas, Kathy Q. Cai, Timothy P. Moran, Mauricio J. Reginato, Ulrike Rennefahrt, and Jeffrey R. Peterson
- 276** **CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration**
Qiusheng Lan, Wei Lai, Yujie Zeng, Lu Liu, Shoufeng Li, Shaowen Jin, Yang Zhang, Xingxi Luo, Heyang Xu, Xianglin Lin, and Zhonghua Chu

Table of Contents


COMPANION DIAGNOSTICS, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 290** Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
 Hao Xu, Liang Chen, Yang Shao, Dongqin Zhu, Xiaofei Zhi, Qiang Zhang, Fengyuan Li, Jianghao Xu, Xisheng Liu, and Zekuan Xu
- 297** The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA
Paul Riviere, Paul T. Fanta, Sadakatsu Ikeda, Joel Baumgartner, Gregory M. Heestand, and Razelle Kurzrock
- 306** Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer
 Kalnisha Naidoo, Patty T. Wai, Sarah L. Maguire, Frances Daley, Syed Haider, Divya Kriplani, James Campbell, Hasan Mirza, Anita Grigoriadis, Andrew Tutt, Paul M. Moseley, Tarek M.A. Abdel-Fatah, Stephen Y.T. Chan, Srinivasan Madhusudan, Emad A. Rhaka, Ian O. Ellis, Christopher J. Lord, Yinyin Yuan, Andrew R. Green, and Rachael Natrajan

 **AC icon indicates AuthorChoice**
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The image shows the cellular distribution of Cy3-labeled Dynamic Polyconjugate (DPC, an RNAi therapeutic delivery vehicle) in clear cell renal cell carcinoma orthotopically engrafted in a mouse kidney. DPC is shown in red, polymeric F-actin is stained green and the DNA in cell nuclei are stained blue.



MODELS AND TECHNOLOGIES

- 316** Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
 Shruthi Naik, Gina D. Galyon, Nathan J. Jenks, Michael B. Steele, Amber C. Miller, Sara D. Allstadt, Lukkana Suksanpaisan, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell, and Amy K. LeBlanc

LETTER TO THE EDITOR

- 327** "Wnt/ β -Catenin in GIST"—Letter
François Bertucci, Pascal Finetti, Alexandre De Nonneville, and Daniel Birnbaum

Molecular Cancer Therapeutics

17 (1)

Mol Cancer Ther 2018;17:1-328.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/17/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/17/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.